Lung Cancer with a High Tumor Mutational Burden.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Advancing precision oncology with AI-powered genomic analysis.Frontiers in pharmacology · 2025
   Review
2. Clinical and Immunological Significance of ANKRD52 in Pan-Cancer.Biochemical genetics · 2024
   Article
3. Bioinformatics roadmap for therapy selection in cancer genomics.Molecular oncology · 2022
   Review
4. Development and validation of an MRI-based nomogram for the preoperative prediction of tumor mutational burden in lower-grade gliomas.Quantitative imaging in medicine and surgery · 2022
   Article
5. Oncolytic virotherapy as immunotherapy.Science (New York, N.Y.) · 2021
   Article
6. High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas.Diagnostic pathology · 2020
   Article
7. Nivolumab-ipilimumab - exploiting the mutation burden of NSCLCs.Nature reviews. Clinical oncology · 2018
   Article

Corrections and comments

• Comment on
  Lung Cancer with a High Tumor Mutational Burden.2018

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as